Sepsis Treatment: New Therapeutic Strategy Tested
Blocking Inflammation in COVID-19: A Double-Edged Sword for Immunity
A new study from the University of São Paulo (USP) sheds light on the complex role of the PAD4 enzyme in COVID-19 and other inflammatory diseases. Researchers have discovered that inhibiting PAD4 can reduce damaging inflammation, but also potentially weaken the body’s ability to build long-term immunity. The findings, led by Caio Santos Bonilha under the supervision of Professor Fernando Queiroz Cunha at the FMRP Pharmacology Department, offer promising avenues for treatment, especially in severe cases, but also highlight the need for careful consideration and further research.
Targeting NETs to Reduce Lung Damage
the study focused on the damaging effects of Neutrophil Extracellular Traps (NETs) – web-like structures released by immune cells that, while intended to trap pathogens, can also contribute to inflammation and tissue damage in the lungs. Bonilha explains, ”We understand that the clinical effect observed is due to the reduction of NETs in the pulmonary microenvironment, which induce tissue damage and, in severe cases, can lead to respiratory failure.” The research demonstrated that inhibiting PAD4, an enzyme crucial for NET formation, effectively prevented their production and lessened the inflammatory response.
Though,the implications extend beyond COVID-19. As PAD4 is involved in a range of inflammatory and autoimmune conditions, inhibiting it could offer therapeutic benefits in diseases like chronic lung ailments, sepsis, and autoimmune disorders where excessive NET formation exacerbates symptoms.
Immunity Trade-Off: A Surprising revelation
Comparing PAD4 inhibition to the use of DNase - an enzyme that breaks down NETs – researchers found both treatments improved clinical symptoms in animal models. Crucially, however, only the PAD4 inhibitor impacted the immune response.
The team discovered that blocking PAD4 compromised the activation of T lymphocytes, vital cells responsible for fighting off viruses and establishing immunological memory. This effect stemmed from reduced antigen presentation by dendritic cells and decreased production of interleukin-2 (IL-2) by the T lymphocytes themselves - a key substance for their proliferation.
“This discovery was not expected and led us to investigate further,” says Bonilha. “We found that the PAD4 inhibitor affects IL-2 production, a basic cytokine for the expansion of T lymphocytes.” Essentially, while the drug reduces inflammation, it may also hinder the body’s ability to mount a robust defense against future infections.
Navigating the Risks and Potential Benefits
The researchers emphasize the need for cautious evaluation of PAD4 inhibitor use. They hypothesize that it could be particularly valuable in severe COVID-19 cases where uncontrolled inflammation poses a greater threat then the virus itself. Though,it might potentially be unsuitable for patients with weakened immune systems or those requiring a strong,lasting immune response.
Bonilha suggests that DNase might potentially be a preferable first-line therapy for targeting NETs in infectious diseases. “It is reasonable to suppose that the first choice in a therapy aiming at NETs… is with the use of DNASE,because it has an effect similar to the inhibitor of PAD4 on neutralization of tissue damage,but maintaining immunological memory formation.”
Combination Therapies and Future Research
The possibility of combining PAD4 inhibitors with immunomodulatory agents is also being explored, mirroring approaches used with corticosteroids – another class of anti-inflammatory drugs that can suppress the immune system.
Further preclinical studies, particularly in models of long COVID, are essential.Rigorous safety and efficacy assessments are also paramount before any human trials can commence. If these studies yield positive results, clinical testing could begin within the next few years.
Bonilha underscores the importance of continued investment in scientific research within Brazil. “It is indeed essential that research such as this will continue to be developed in the country.Brazil has full potential to lead discoveries with global impact as there is continuous thankfulness of national science.”